Home / Research library / Livagen
Livagen: molecular data, studies & sources
Livagen is catalogued here as a research compound. This profile brings together the molecular source record, selected indexed publications and available supplier comparisons. Evidence for a named substance does not authenticate a commercial product.
Compiled by PeptideTech Editors · Sources checked · Selected bibliography, not a systematic review
Molecular formula, weight & structure
- Molecular formula (MF)
- C18H31N5O9
- Molecular weight (MW)
- 461.5 g/mol
- PubChem compound ID
- 87919683
- Record title
- Livagen
Values describe the selected PubChem molecular entity. Counterions, salt forms, hydration and sequence changes can alter the supplied material. Confirm the exact identity against the supplier specification.
Source: PubChem CID 87919683 · retrieved 2026-09-21

Chemical identifiers and source data
- IUPAC name
- (4S)-5-[[(2S)-3-carboxy-1-[[(1S)-1-carboxyethyl]amino]-1-oxopropan-2-yl]amino]-4-[[(2S)-2,6-diaminohexanoyl]amino]-5-oxopentanoic acid
- InChIKey
- IKVDKWACACMDLR-BJDJZHNGSA-N
- SMILES
- C[C@@H](C(=O)O)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCCN)N
Human and clinical studies
Selected human-study records are shown with their indexed or reviewed study type. Check the original article for the intervention, formulation and controls; the molecule can also be a comparator or measured variable.
No matching human study was retained in this selected bibliography. This is a documented evidence gap in our selection, not proof that no study exists.
Preclinical research, reviews & other publications
Animal studies, laboratory experiments, reviews and other indexed papers answer different questions. A review is secondary evidence; a case report does not estimate how often an outcome occurs.
- Research publication · design requires review
[Genomic instability in atherosclerosis].
Dzhokhadze TA, Buadze TZh, Gaiozishvili MN et al. · Georgian medical news · 2014
PMID 25541832
- Research publication · design requires review
Activation of pericentromeric and telomeric heterochromatin in cultured lymphocytes from old individuals.
Lezhava T, Jokhadze T · Annals of the New York Academy of Sciences · 2007
PMID 17460203 · DOI: 10.1196/annals.1395.043
- Preclinical / laboratory research
Tissue-specific effects of peptides.
Khavinson VK · Bulletin of experimental biology and medicine · 2001
PMID 11713572 · DOI: 10.1023/a:1013058701974
- Research publication · design requires review
Effects of short peptides on lymphocyte chromatin in senile subjects.
Khavinson VKh, Lezhava TA, Malinin VV et al. · Bulletin of experimental biology and medicine · 2004
PMID 15085253 · DOI: 10.1023/b:bebm.0000024393.40560.05
- Research publication · design requires review
[Effect of peptide bioregulator and cobalt ions on the activity of NORs and associations of acrocentric chromosomes in lymphocytes of patients with hypertrophic cardiomyopathy and their relatives].
· Georgian medical news · 2014
PMID 25341254
Livagen supplier sources
Scientific sources describe molecules and experiments. The commercial links below identify recorded supplier packages. A publication or chemical database entry does not verify the seller, purity, sterility or contents of a lot. Some links are affiliate links; see our disclosure.
Compare all Livagen sizes, forms and supplier prices →
| Supplier | Recorded packages | Example source listing |
|---|---|---|
| Amino USAUSD | 20mg Vial1 recorded offers | 20mg Vial · $45.00Checked Sep 16, 2026Supplier listing |
Reference sources & further reading
- PubChem compound record 87919683 — chemical identity and structure.
- Wikipedia: Livagen — Background encyclopedia; not a primary clinical source.
The citations above link directly to publication records. Encyclopedia links are background reading and are not used to establish clinical effectiveness.
Search for additional research
These links run searches; their results have not been individually reviewed and can include unrelated compounds.
Research information is not a dosing guide or a recommendation for personal use. Study findings are specific to the formulation, population and methods tested. Read our source and correction policy.
Related research profiles
Bronchogen
C18H30N4O9
446.5 g/mol · PubChem CID 11690869
6 selected publications · 0 human study records
Cardiogen
Molecular identity needs further verification
1 selected publications · 0 human study records
Cartalax
C12H19N3O8
333.29 g/mol · PubChem CID 87815447
0 selected publications · 0 human study records
Chonluten
C11H17N3O8
319.27 g/mol · PubChem CID 194641
1 selected publications · 0 human study records
Cortagen
C17H26N4O9
430.4 g/mol · PubChem CID 18439621
5 selected publications · 0 human study records
Epithalon
C14H22N4O9
390.35 g/mol · PubChem CID 219042
4 selected publications · 1 human study records